$333.04
This code describes a deep muscle biopsy. Code 89049 identifies contracture testing of muscle; the biopsy alone does not establish that the test was performed.
On this page
CMS RVU26D · Effective 2026-10-01
89049 MH susceptibility test Medicare reimbursement rates in Wyoming
Reports specialized muscle contracture testing that evaluates malignant hyperthermia susceptibility, typically after a patient or family history raises concern. Compare 89049 office and facility rates across CMS payment localities in Wyoming.
Amounts below use the non-QP conversion factor for participating physicians. These are base physician payments before claim-level adjustments, not patient costs or total hospital charges.
What does Medicare pay for 89049 in Wyoming?
Wyoming has 1 payment locality in this comparison. Use the service location to choose the applicable amount. These are the supported base rates for the payment area shown below, using the same CMS release.
Office / nonfacility
$352.82
1 of 1 localities have a supported rate.
Payment area: Wyoming**
One mapped payment locality.
Facility setting
$56.89
1 of 1 localities have a supported rate.
Payment area: Wyoming**
One mapped payment locality.
These are locality ranges, not averages or address-specific quotes. A facility-setting amount covers the physician service; it does not include a hospital’s separate bill. Choose a locality below to inspect its calculation, compare other payment areas, or price a percentage of Medicare.
Laboratory testing
About 89049: Malignant hyperthermia contracture test
Reports specialized muscle contracture testing that evaluates malignant hyperthermia susceptibility, typically after a patient or family history raises concern.
This specialized test evaluates how fresh skeletal muscle responds to caffeine and halothane under controlled laboratory conditions. A muscle specimen is obtained for testing, generally through a biopsy, and the contracture response helps assess susceptibility to malignant hyperthermia. It is used in specialized testing settings for patients with a concerning personal history or a family history of malignant hyperthermia susceptibility; it is not a test for treating an acute anesthetic crisis.
Report the code when the contracture testing itself is performed, rather than for a muscle biopsy alone or for genetic testing alone. Documentation should identify the clinical reason for testing and support that the muscle specimen underwent the contracture procedure, with the resulting interpretation recorded. CMS assigns physician fee schedule values to this service; those values contribute to payment calculation. The supplied CMS rules list no code-specific payment adjustments.
Where the value comes from
- Work RVU1.37 · 13%
- Practice expense (office) RVU9.06 · 85%
- Malpractice RVU0.18 · 2%
This summary was written with AI assistance from CMS physician fee schedule data and checked against the CMS billing rules shown here. Rates on this page come directly from CMS files.
89049 compared with similar codes
Office rates for Wyoming, from the same CMS release.
81479
No office rateUnlisted molecular pathology
This is an unlisted molecular pathology code, not the caffeine-halothane contracture procedure. Select coding based on the actual molecular assay when genetic testing is performed.
Compare 89049 by payment locality
Find the payment area for your service address, then open its rate page for calculation inputs, release history and the percentage-of-Medicare tool. A city may cross payment-area boundaries; the ZIP lookup above helps resolve the location.
1 of 1 payment localities
Wyoming** →
Office / nonfacility
$352.82
Facility
$56.89
Need rates for a whole code list?
Fee-sheet and API access are in early access. Tell us which codes and locations your team needs.
How this local rate is calculated
Each RVU component is multiplied by its own geographic practice cost index (GPCI). The three adjusted components are added, then multiplied by the conversion factor. These are the inputs used for 89049 in Wyoming**.
PPRRVU2026_Oct_nonQPP.csv
11,334
- Code
- 89049
- Physician work
- 1.37
- Practice expense
- 9.06
- Malpractice
- 0.18
GPCI2026.csv
112
- Locality
- Wyoming**
- Physician work
- 1.000
- Practice expense
- 1.000
- Malpractice
- 0.740
| Component | RVU | Locality factor | Adjusted |
|---|---|---|---|
| Physician work | 1.37 | × 1.000 | 1.3700 |
| Practice expense | 9.06 | × 1.000 | 9.0600 |
| Malpractice | 0.18 | × 0.740 | 0.1332 |
| Total RVUs | 10.5632 | ||
| Conversion factor | × 33.4009 | ||
Office / nonfacility rate, Wyoming**$352.82
Explore RVUs, geographic factors and the full formula
Office / nonfacility
| Component | RVU | Local GPCI |
|---|---|---|
| Work | 1.37 | 1 |
| Practice expense | 9.06 | 1 |
| Malpractice | 0.18 | 0.74 |
(1.37 × 1 + 9.06 × 1 + 0.18 × 0.74) × $33.4009 = $352.82
Facility
| Component | RVU | Local GPCI |
|---|---|---|
| Work | 1.37 | 1 |
| Practice expense | 0.2 | 1 |
| Malpractice | 0.18 | 0.74 |
(1.37 × 1 + 0.2 × 1 + 0.18 × 0.74) × $33.4009 = $56.89
The office and facility calculations use their respective practice-expense RVUs. The facility amount here is the physician fee, not a separate hospital or facility bill.
89049 billing questions
When is this code appropriate instead of a genetic test?
Use it for the caffeine-halothane contracture test performed on skeletal muscle. A molecular assay is a different service and should be coded according to the assay performed.
Does this code report the muscle biopsy?
It identifies the contracture testing, not a standalone biopsy. The biopsy is the source of the muscle specimen; any separate reporting of tissue collection must reflect a distinct service and applicable coding guidance.
What documentation supports reporting the test?
Document the clinical concern, such as a relevant personal or family history, and that fresh skeletal muscle underwent contracture testing. Retain the test findings and interpretation.
Is this code used to evaluate an acute reaction during anesthesia?
No. This test evaluates susceptibility using a muscle specimen; it does not describe management of an acute malignant hyperthermia event.
Should a body-fluid cell count code be reported for the muscle specimen?
No. A body-fluid cell count describes a different laboratory service and does not represent contracture testing of skeletal muscle.
Where these rates come from
FeeBase calculates base physician payments from CMS work, practice-expense, and malpractice RVUs, adjusted by each locality’s geographic indices and the applicable conversion factor. Unavailable or separately priced services are labeled rather than assigned a made-up amount.
Source: RVU26D. Effective 2026-10-01 through the day before 2027-01-01.
11,33188740,,Transcutaneous carboxyhb,X,,0.00,0.00,,0.00,,0.00,0.00,0.00,9,XXX,0.00,0.00,0.00,9,9,9,9,9,9,,33.4009,09,0,99,0.00,0.00,0.00
11,33288741,,Transcutaneous methb,X,,0.00,0.00,,0.00,,0.00,0.00,0.00,9,XXX,0.00,0.00,0.00,9,9,9,9,9,9,,33.4009,09,0,99,0.00,0.00,0.00
11,33388749,,Unlisted in vivo lab service,X,,0.00,0.00,,0.00,,0.00,0.00,0.00,9,XXX,0.00,0.00,0.00,9,9,9,9,9,9,,33.4009,09,0,99,0.00,0.00,0.00
11,33489049,,Chct for mal hyperthermia,A,,1.37,9.06,,0.20,,0.18,10.61,1.75,0,XXX,0.00,0.00,0.00,0,0,0,0,0,9,,33.4009,09,0,99,0.00,0.00,0.00
11,33589050,,Body fluid cell count,X,,0.00,0.00,,0.00,,0.00,0.00,0.00,9,XXX,0.00,0.00,0.00,9,9,9,9,9,9,,33.4009,09,0,99,0.00,0.00,0.00
11,33689051,,Body fluid cell count,X,,0.00,0.00,,0.00,,0.00,0.00,0.00,9,XXX,0.00,0.00,0.00,9,9,9,9,9,9,,33.4009,09,0,99,0.00,0.00,0.00
11,33789055,,Leukocyte assessment fecal,X,,0.00,0.00,,0.00,,0.00,0.00,0.00,9,XXX,0.00,0.00,0.00,9,9,9,9,9,9,,33.4009,09,0,99,0.00,0.00,0.00
10902402,WA,99,REST OF WASHINGTON,1.013,1.053,0.761
11011402,WV,16,WEST VIRGINIA,1.000,0.869,1.431
11106302,WI,00,WISCONSIN,1.000,0.958,0.308
11203602,WY,21,WYOMING**,1.000,1.000,0.740
113"MAC Assignments as of November 22, 2023",,,,,,
114,,,,,,
115*Work GPCI reflects a 1.5 floor in Alaska established by the MIPPA.,,,,,,